Using the industry peer median P/E Multiples multiple (trailing + forward), BrainsWay Ltd. (BWAY) has a fair value of $5.54 based on 4 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| BrainsWay Ltd.BWAY | 364 | 47.7x | 549.4x |
| Tactile Systems Technology, Inc. | 587 | 31.7x | 18.9x |
| Delcath Systems, Inc. | 399 | 169.8x | — |
| Viemed Healthcare, Inc. | 353 | 24.9x | 32.9x |
| 908 Devices Inc. | 309 | 15.1x | — |
| Industry Median | 28.3x | 25.9x | |
| (*) Profit after tax | 8 | 1 | |
| Equity Value | 218 | 17 | |
| (/) Outstanding shares | 21 | 21 | |
| Fair Price | $10 | $1 | |
Using the industry peer median EV/EBITDA multiple (trailing + forward), BrainsWay Ltd. (BWAY) has a fair value of $6.71 based on 3 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| BrainsWay Ltd.BWAY | 364 | 51.3x | 66.7x |
| Tactile Systems Technology, Inc. | 587 | 14.5x | 16.9x |
| Delcath Systems, Inc. | 399 | 92.3x | 76.1x |
| Viemed Healthcare, Inc. | 353 | 6.9x | 8.3x |
| Industry Median | 14.5x | 16.9x | |
| (*) EBITDA | 6 | 5 | |
| = Enterprise Value | 85 | 77 | |
| (-) Net Debt | -61 | -61 | |
| Equity Value | 147 | 138 | |
| (/) Outstanding shares | 21 | 21 | |
| Fair Price | $7 | $7 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), BrainsWay Ltd. (BWAY) has a fair value of $9.40 based on 10 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| BrainsWay Ltd.BWAY | 364 | 5.8x | 7.5x |
| NeuroPace, Inc. | 623 | 6.7x | 6.8x |
| Tactile Systems Technology, Inc. | 587 | 1.6x | 1.8x |
| Cerus Corporation | 523 | 2.9x | 3.0x |
| Delcath Systems, Inc. | 399 | 4.2x | 3.4x |
| Viemed Healthcare, Inc. | 353 | 1.3x | 1.6x |
| 908 Devices Inc. | 309 | 3.8x | 3.9x |
| Sight Sciences, Inc. | 286 | 3.0x | 2.9x |
| RxSight, Inc. | 239 | 1.7x | 1.6x |
| Senseonics Holdings, Inc. | 224 | 6.4x | 3.7x |
| CVRx, Inc. | 180 | 2.7x | 2.7x |
| Industry Median | 3.0x | 3.0x | |
| (*) Revenue | 53 | 40 | |
| = Enterprise Value | 156 | 120 | |
| (-) Net Debt | -61 | -61 | |
| Equity Value | 218 | 181 | |
| (/) Outstanding shares | 21 | 21 | |
| Fair Price | $10 | $9 | |
Using the PEG framework with historical EPS growth of 25.0%, the company has a fair value of $9.00 based on TTM EPS (FY2025) of $0.36. The current PEG ratio is 0.16.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
Growth above 25% is capped — hypergrowth may not be sustainable long-term.
| EPS Growth RateHistorical | 300.0% |
| Adjusted Growth (clamped 8–25%)Clamped | 25.0% |
| Fair P/E | 25.0x |
| TTM EPS (FY2025) | $0.36 |
| Fair Value | $9.00 |
No analyst estimates available.
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-6.5M | $-0.21 | — |
| FY2022 | $-13.3M | $-0.43 | — |
| FY2023 | $-4.2M | $-0.13 | — |
| FY2024 | $2.9M | $0.09 | — |
| FY2025 | $7.7M | $0.36 | +300.0% |
4Y Historical EPS CAGR: 300.0%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.